RDHL News and Press, Redhill Biopharma Ltd.

RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study PR Newswire First patient enrolled in the global, 300-patient, Phase 2 adaptive platform trial arm of RHB-107 (upamostat) 1 for early COVID-19 outpatient treatment, funded through non-...

2024-04-08 14:07:22 ET More on RedHill RedHill Biopharma looks to raise $1.25M in a direct offering of securities RedHill gains after new patent grant for Talicia for H. pylori treatment through 2042 Financial information for RedHill Read the full article o...

RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights PR Newswire RedHill continues corporate transformation to focus on U.S. government-funded pipeline development in underserved, sizeable therapeutic areas with a disciplined cost-base ...

2024-04-02 07:32:23 ET More on RedHill RedHill gains after new patent grant for Talicia for H. pylori treatment through 2042 Financial information for RedHill Read the full article on Seeking Alpha For further details see: RedHill Biopharma looks to raise...

RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price PR Newswire TEL AVIV, Israel and RALEIGH, N.C. , April 2, 2024 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialt...

RedHill Announces New USPTO Patent Covering Talicia® Through 2034 PR Newswire U.S. Patent and Trademark Office (USPTO) issues new patent covering Talicia 1 as an all-in-one treatment of Helicobacter pylori (H. pylori), supporting Talicia protection until Feb...

RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs PR Newswire The U.S. government's Chemical Medical Countermeasures (Chem MCM) Program and Chemical Countermeasures Research Program (CCRP), managed respectively by ASPR/BARDA and NIH/NIAID, in...

RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication PR Newswire The data, published in the International Journal of Molecular Sciences, demonstrate that opaganib significantly improved long-term survival in an in vivo model of...

2024-02-09 16:29:27 ET More on RedHill RedHill gains after new patent grant for Talicia for H. pylori treatment through 2042 RedHill shares rally 20% on positive data for two antiviral drugs Financial information for RedHill Read the full article on Seeking...

RedHill Biopharma Announces Closing of $8 Million Registered Direct Offering PR Newswire TEL AVIV , Israel and RALEIGH, N.C. , Jan. 26, 2024 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceu...